ArticleDiabetology & metabolic syndrome2025
Associations of inflammation-related hematological profile with the early-stages of cardiovascular-kidney-metabolic syndrome and the mediating role of body composition: evidence from the China National Health Survey.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative Cardiac Risk Stratification in Dogs with Mammary Tumors Using Two-Dimensional Speckle Tracking Echocardiography: A Pilot Study.Animals : an open access journal from MDPI · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundChronic low-grade inflammation is increasingly recognized as a pivotal driver in the development of early-stage cardiovascular-kidney-metabolic (CKM) syndrome. Nonetheless, the complex interplay among inflammation-associated hematological indices, body composition, and CKM risk remains inadequately understood.
methodsIn this cross-sectional study, data from 5,692 participants of the China National Health Survey (CNHS) were analyzed. We employed advanced machine learning techniques-including Random Forest, Least Absolute Shrinkage and Selection Operator(LASSO) regression, and eXtreme Gradient Boosting (XGBoost)-in conjunction with traditional epidemiological methods to assess the predictive value of an inflammation-related hematological profile for early-stage CKM. Restricted cubic spline regression was used to explore nonlinear dose-response relationships, and generalized structural equation modeling investigated the mediating role of body composition in the inflammation-CKM pathway.
resultsSix biomarkers-Neutrophil-to-HDL ratio (NHR), Monocyte-to-HDL ratio (MHR), High-sensitivity C-reactive protein/albumin ratio (CAR), High-fluorescence reticulocyte fraction (HFR), Reticulocyte production index (RPI), and Reticulocyte count (RET#)-were consistently prioritized across models. Participants in the highest quartiles of NHR, MHR, and RET# exhibited markedly elevated odds of early-stages of CKM (OR = 10.4, 7.75, and 6.99, respectively; all P for trend < 0.0001). Nonlinear analyses revealed critical thresholds-specifically, NHR > 7.05 and MHR > 0.66-beyond which early-stages of CKM risk escalated steeply. Mediation analyses indicated that imbalances in body composition, particularly increased adiposity and reduced muscle mass, accounted for 20-57% of the association between systemic inflammation and early-stage of CKM syndrome. Subgroup analyses further underscored that the predictive impact of reticulocyte parameters was amplified in smokers and individuals aged < 60 years.
conclusionThis study validates NHR and MHR as robust, clinically actionable biomarkers for early CKM screening. The delineated nonlinear thresholds and the mediating effects of body composition provide a strategic framework for targeted interventions-prioritizing anti-inflammatory treatments in high-risk groups (e.g., smokers with RET# >143.03 × 10³/µL) and muscle-preserving therapies to mitigate sarcopenic adiposity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.